Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Co-primary endpoints based on Allurion Balloon subject responders and a comparison of percent total body weight loss between groups were measured at Week 48, approximately eight weeks after the ...

patients treated with Allurion Balloon did see a greater weight loss compared with control at week 48 (3.77% mean difference in total body weight loss [TBWL]; 2.69% superiority margin; P ...

Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would ...

Co-primary endpoints based on Allurion Balloon subject responders and a comparison of percent total body weight loss between groups were measured at Week 48, approximately eight weeks after the ...

NATICK, Mass., January 21, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable ...

(RTTNews) - Allurion Technologies, Inc. (ALUR) a Massachusetts-based medical device company Tuesday announced the issuance of a new U.S. patent for its advanced weight loss device to treat obesity ...

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S ...